10.30.26 -- Escape The Biotech's Valley Of Death

Fast‑track, data‑driven formulation strategies align early decisions with long‑term goals, enabling First‑in‑Human progress while reducing risk, avoiding rework, and supporting manufacturing.

Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment. 

A chemoenzymatic process creates uniform DAR2 ADCs from native mAbs through glycan remodeling and click chemistry, delivering stronger in vivo efficacy than a comparable marketed ADC.

Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

Combining a precision dosing device with multiparticulate drug delivery enables accurate, repeatable oral dosing, supporting personalized treatment and improved patient outcomes.

 Early drug development demands speed, but some decisions carry long-term consequences. Learn which process and analytical choices require teams to look beyond the next milestone.

Dive into the scope of <382> for pharmaceutical closures and the regulatory landscape, which includes new required tests, instrumentation for compliance, and recommendations on implementation.

Pharmaceutical manufacturing facilities require active management and engineering expertise to balance costs, plan long-term infrastructure, and minimize production downtime.